Popular on TelAve
- Century Fasteners Corp. Exhibiting at the 2025 International Paris Air Show
- Pregis Empowers Foam-in-Place Customers to Fight Water Insecurity with Inspyre Film
- Fusion Marketing Group Celebrates 15 Years of Transforming Healthcare Recruitment Marketing
- Western Carolina Emergency Network Accepts 2025 ReadyCommunities Partnership/CCROA National Service Award for Collaboration to Augment Local Response
- Experience Trembling Firsthand with the New AgeMan® Tremor Simulator
- Kaplan Morrell Applauds Passage of Landmark Workers' Compensation Reform in Colorado
- Shelter Structures America Appoints Shannon Heller as New Inventory Manager, Bolstering Operational Excellence in the Commercial Tent Industry
- Zareef Hamid Analyzes How AI is Redefining Financial Services
- L2uMA Outreach Program to Support Mobile Healthcare Expansion for 65+ Population
- $3.9M Q1 2025 Revenue Following $39M in Cybersecurity Contracts for Education and Transportation Sectors: Cycurion, Inc
China Biopsy Market Forecast by Cancer Segment & Company Analysis
TelAve News/10628304
Cancer is the leading cause of mortality in China. There approximately 4.3 Million cancer cases and 2.9 Million cancer death occurred over in 2018. So an average of 7 people was diagnosed with cancer, while 4 people died of cancer every minute in China. China has 40% higher motility rate compared to the United Kingdom and the United States. Imaging tests like X-rays and CT scans assist in discovering areas of concerns, but they can't differentiate between cancerous and noncancerous cells. For the diagnosis of cancer, a biopsy is the only sure way to identify most cancers. According to Renub Research report, China Biopsy Market is expected to reach USD 8.1 Billion by the end of the year 2026.
How COVID-19 affects China Biopsy Industry
The Coronavirus outbreak has come as a massive blow on the biopsy diagnostics centres, hospitals, supply chain and clinical trials of the biopsy industry. As per our findings, the biopsy market in China got affected a bit from December 2019 to April 2020. Read the complete analysis of COVID-19 in our report. As for how this pandemic is affecting the biopsy industry in China and when it's going to revive.
Reasons for Growth in Cancer Cases and High Mortality Rate in China
The rise in cancer cases has been driven by an ageing population and the prevalence of lifestyle factors such as smoking, stress and sedentary lifestyle.
More on TelAve News
The prime reasons for the higher mortality in China are due to its low rate of early-stage cancers detection, and another reason is that China still has non-uniformed clinical cancer treatment strategies performed by different regions.
Top 3 Types of Cancers in China
Chinese population is mostly affected by three types of cancer Breast Cancer, Liver cancer, Colon and Rectum cancer. Breast cancer is one of the most common cancer among women in China. Our study also reveals that breast cancer rates are higher in urban areas of China than in rural areas. As with the rapid development of China's economy, more and more people have moved from rural areas to large cities.
Request a free Brochure copy of the report: https://www.renub.com/request-sample-page.php?gturl=china-biopsy-market-p.php
This is a known fact that having more than one child lowers breast-cancer risk. But China had 1 child policy from 1979, and since most of the women work in the city, they have to follow the policy to avoid penalty. Although this one-child rule was repealed in 2015 with two-child policy rule, however, it will take 15 to 20 years for this policy to show any result.
Renub Research report titled "China Biopsy Market, by Cancer Segment (Breast cancer, prostate cancer, lung cancer, liver cancer, thyroid cancer, kidney cancer, colon & rectum cancer, kidney cancer, leukemia, pancreas cancer, and bladder cancer), Volume of Biopsy and Patient Diagnosed Numbers, Company (C. R. Bard, Inc., Becton, Dickinson and Company, Cardinal Health, Inc, Boston Scientific Corporation and Hologic, Inc.)" provides an all-encompassing analysis on the Biopsy Market in China.
More on TelAve News
About Company:
Renub Research is a Market Research and Consulting Company. We have more than 10 years of experience especially in international Business-to-Business Researches, Surveys and Consulting. We provide wide range of business research solutions that helps companies in making better business decisions. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses. Our wide clientele comprises of major players in Life Sciences, Information Technology, Telecom, Financial Services (Banking, Insurance), Energy, Retail, Manufacturing, Automotive, and Social sector. Our clients rely on our market analysis and data to make informed knowledgeable decisions. We are regarded as one of the best providers of knowledge. Our pertinent analysis helps consultants, bankers and executives to make informed and correct decisions.
Contact Us:
Renub Research
Phone No: +1 678-302-0700 (USA) | +91-120-421-9822 (IND)
Email : info@renub.com
Web: https://www.renub.com
Fallow on Linkedin: https://www.linkedin.com/company/renub-research
How COVID-19 affects China Biopsy Industry
The Coronavirus outbreak has come as a massive blow on the biopsy diagnostics centres, hospitals, supply chain and clinical trials of the biopsy industry. As per our findings, the biopsy market in China got affected a bit from December 2019 to April 2020. Read the complete analysis of COVID-19 in our report. As for how this pandemic is affecting the biopsy industry in China and when it's going to revive.
Reasons for Growth in Cancer Cases and High Mortality Rate in China
The rise in cancer cases has been driven by an ageing population and the prevalence of lifestyle factors such as smoking, stress and sedentary lifestyle.
More on TelAve News
- $12.8 Million Net Revenue for 2024 for Cloud-Based Crowdsourcing Recruitment and SaaS-Enabled HR Solutions Provider: Baiya International Group Inc
- Hire Virtue Announces Executive Sponsorship Opportunity for Houston Hiring Blitz & Job Fair on August 6, 2025
- Inked & Maxim Model Teisha Mechetti Turns Heads—And Builds Community Impact
- Plan to Launch Silo Technologies' Cybersecurity Pilot Program for Ultimate Nationwide Deployment via Exclusive Partnership: Stock Symbol: BULT
- Robert Michael & Co. Real Estate Team Celebrates Industry Recognition and Showcases Premier Central Florida Listings
The prime reasons for the higher mortality in China are due to its low rate of early-stage cancers detection, and another reason is that China still has non-uniformed clinical cancer treatment strategies performed by different regions.
Top 3 Types of Cancers in China
Chinese population is mostly affected by three types of cancer Breast Cancer, Liver cancer, Colon and Rectum cancer. Breast cancer is one of the most common cancer among women in China. Our study also reveals that breast cancer rates are higher in urban areas of China than in rural areas. As with the rapid development of China's economy, more and more people have moved from rural areas to large cities.
Request a free Brochure copy of the report: https://www.renub.com/request-sample-page.php?gturl=china-biopsy-market-p.php
This is a known fact that having more than one child lowers breast-cancer risk. But China had 1 child policy from 1979, and since most of the women work in the city, they have to follow the policy to avoid penalty. Although this one-child rule was repealed in 2015 with two-child policy rule, however, it will take 15 to 20 years for this policy to show any result.
Renub Research report titled "China Biopsy Market, by Cancer Segment (Breast cancer, prostate cancer, lung cancer, liver cancer, thyroid cancer, kidney cancer, colon & rectum cancer, kidney cancer, leukemia, pancreas cancer, and bladder cancer), Volume of Biopsy and Patient Diagnosed Numbers, Company (C. R. Bard, Inc., Becton, Dickinson and Company, Cardinal Health, Inc, Boston Scientific Corporation and Hologic, Inc.)" provides an all-encompassing analysis on the Biopsy Market in China.
More on TelAve News
- AI-Based Neurotoxin Countermeasure Initiative Launched to Address Emerging National Security Needs: Renovaro, Inc. (N A S D A Q: RENB)
- The Naturist World Just Shifted — NaturismRE Ignites a Global Resurgence
- Ace8 Launches Cutting-Edge Observability Service to Empower Modern IT Operations
- AceMQ Unveils Advanced Containerization Solutions to Accelerate Digital Transformation
- $796,000 in Q2 Revenue Marks Highest Earnings to Date on 3 Trailing Quarters of Profitability in Multi-Billion Homebuilding Sector: Stock Symbol: IVDN
About Company:
Renub Research is a Market Research and Consulting Company. We have more than 10 years of experience especially in international Business-to-Business Researches, Surveys and Consulting. We provide wide range of business research solutions that helps companies in making better business decisions. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses. Our wide clientele comprises of major players in Life Sciences, Information Technology, Telecom, Financial Services (Banking, Insurance), Energy, Retail, Manufacturing, Automotive, and Social sector. Our clients rely on our market analysis and data to make informed knowledgeable decisions. We are regarded as one of the best providers of knowledge. Our pertinent analysis helps consultants, bankers and executives to make informed and correct decisions.
Contact Us:
Renub Research
Phone No: +1 678-302-0700 (USA) | +91-120-421-9822 (IND)
Email : info@renub.com
Web: https://www.renub.com
Fallow on Linkedin: https://www.linkedin.com/company/renub-research
0 Comments
Latest on TelAve News
- Colorado Scenthound Locations Partner with Humane Colorado to Give Adopted Dogs a "Clean Start"
- Endoacustica Europe Unveils iPhone 13 Pro Max Spy Phone—Pure Hardware, Zero Software Changes
- Suzanne Harp named Managing Director in Texas, USA
- $10 Million Acquisition of GXR World Sports Assets Energizes Global Launch of Sports.com Super App by Online Lottery-Sports Game Provider: Lottery.com
- Shop American Made Goods: New Online Marketplace My American Goods Curates the Best of U.S. Made
- Investor Spotlight: Cycurion, Inc. (N A S D A Q: CYCU) Secures $69M in Contracts Amid Surging Demand for AI-Powered Cybersecurity Solutions
- $328 Million Global Stroke Rehab Market Opportunity Awaits AI Telehealth Leader Following Selection for NIH Funded Phase 3 Clinical Study: VSee Health
- Ascent Solar Technologies Enters Collaborative Agreement Notice with NASA to Advance Development of Thin-Film PV Power Beaming Capabilities: ASTI
- VoodooSoft Unveils SiriusLLM: The World's First ChatGPT-Like AI Malware Detection Engine
- This Ain't Press. This Is Pressure — Star Command by RansomXX is Out Now
- An Exclusive VIP Reception Honoring Vocal Prodigy Alliana Lili Yang's Remarkable Achievements and Magazine Cover Spotlight
- Joyce Carol Oates Returns to Hard Case Crime With DOUBLE TROUBLE
- New AI Academy Helps Therapists Embrace Tech Without Losing Their Humanity
- IQSTEL Surges Toward $400M Run Rate with $101.5M in Revenue—Reinforces Billion-Dollar Vision Backed by Fintech, AI, and Cybersecurity
- Alpha Modus Files 7th IP Action Against Rackspace Following $3M CEO Investment and Strategic Partnership Expansion
- Mortgage Rates And Demand Are Stuck In A Holding Pattern
- Coker Completes Acquisition of Healthcare Cost Solutions, a Leading Expert in Technology-Enabled Compliance Services
- Keepy Uppy™ by Ollyball Wins Prestigious 2025 Influencer Award from Clamour & The Toy Association; Announces Fall 2025 Launch at Target Stores
- K2 Integrity's U.S. and EMEA Teams Recognized in Chambers and Partners 2025 Guides
- A rare chance to own a multi-family property in the heart of Bay Ridge